Involvement of β-catenin expression in hepatocellular carcinoma prognosis in a cohort of patients undergoing curative treatment

IF 3.2 2区医学 Q1 SURGERY

Surgery Pub Date : 2025-02-01 DOI:10.1016/j.surg.2024.09.035

Noelia De-Armas-Conde PhD, MD , Francisco Javier González-Rico PhD , Isabel Jaén-Torrejimeno PhD, MD , Jaime M. Merino PhD , Diego López-Guerra PhD, MD , Ana Ordiales-Talavero PhD, MD , Adela Rojas-Holguín MD , Beatriz Marín-Díaz , Julen Ramón-Rodríguez PhD, MD , Laura Ordóñez-Mata , Pedro M. Fernández-Salguero PhD , Gerardo Blanco-Fernández PhD, MD

{"title":"Involvement of β-catenin expression in hepatocellular carcinoma prognosis in a cohort of patients undergoing curative treatment","authors":"Noelia De-Armas-Conde PhD, MD , Francisco Javier González-Rico PhD , Isabel Jaén-Torrejimeno PhD, MD , Jaime M. Merino PhD , Diego López-Guerra PhD, MD , Ana Ordiales-Talavero PhD, MD , Adela Rojas-Holguín MD , Beatriz Marín-Díaz , Julen Ramón-Rodríguez PhD, MD , Laura Ordóñez-Mata , Pedro M. Fernández-Salguero PhD , Gerardo Blanco-Fernández PhD, MD","doi":"10.1016/j.surg.2024.09.035","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Hepatocellular carcinoma is a tumor of epithelial origin that arises from the action of different carcinogens on the hepatocytes and has a high worldwide incidence. The prognostic markers of this disease have not been completely established. Mutations in the gene encoding β-catenin are overexpressed in hepatocellular carcinoma. The objective of our study was to correlate the molecular expression of β-catenin in hepatocellular carcinoma with the already known prognostic markers.</div></div><div><h3>Methods</h3><div>We conducted an observational and prospective cohort study on adult patients diagnosed with hepatocellular carcinoma from whom samples of nontumor and tumor liver parenchyma were taken intraoperatively to correlate the molecular expression of β-catenin in hepatocellular carcinoma with the known prognostic markers.</div></div><div><h3>Results</h3><div>A total of 81 samples were collected, of which 48 met the inclusion criteria. The final sample was divided into patients with a diagnosis of hepatocellular carcinoma on a cirrhotic liver, corresponding to 31 patients (64.6%), and patients with a diagnosis of hepatocellular carcinoma on a noncirrhotic liver, corresponding to 17 patients (35.4%). We found that overexpression of β-catenin and the neutrophil/lymphocyte ratio are independently related to disease-free survival, and both overexpression and molecular repression of β-catenin are independently related.</div></div><div><h3>Conclusion</h3><div>Molecular overexpression of β-catenin in hepatocellular carcinoma compared with nontumor tissue is associated with worse disease-free survival, and its combination with a high neutrophil-lymphocyte ratio worsens this prognosis.</div></div>","PeriodicalId":22152,"journal":{"name":"Surgery","volume":"178 ","pages":"Article 108885"},"PeriodicalIF":3.2000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0039606024008134","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Hepatocellular carcinoma is a tumor of epithelial origin that arises from the action of different carcinogens on the hepatocytes and has a high worldwide incidence. The prognostic markers of this disease have not been completely established. Mutations in the gene encoding β-catenin are overexpressed in hepatocellular carcinoma. The objective of our study was to correlate the molecular expression of β-catenin in hepatocellular carcinoma with the already known prognostic markers.

Methods

We conducted an observational and prospective cohort study on adult patients diagnosed with hepatocellular carcinoma from whom samples of nontumor and tumor liver parenchyma were taken intraoperatively to correlate the molecular expression of β-catenin in hepatocellular carcinoma with the known prognostic markers.

Results

A total of 81 samples were collected, of which 48 met the inclusion criteria. The final sample was divided into patients with a diagnosis of hepatocellular carcinoma on a cirrhotic liver, corresponding to 31 patients (64.6%), and patients with a diagnosis of hepatocellular carcinoma on a noncirrhotic liver, corresponding to 17 patients (35.4%). We found that overexpression of β-catenin and the neutrophil/lymphocyte ratio are independently related to disease-free survival, and both overexpression and molecular repression of β-catenin are independently related.

Conclusion

Molecular overexpression of β-catenin in hepatocellular carcinoma compared with nontumor tissue is associated with worse disease-free survival, and its combination with a high neutrophil-lymphocyte ratio worsens this prognosis.

Abstract Image

查看原文本刊更多论文

接受根治性治疗的一组患者中β-catenin的表达与肝细胞癌预后的关系。

背景：肝细胞癌是一种上皮源性肿瘤，由不同的致癌物质作用于肝细胞而产生，在全球发病率很高。这种疾病的预后指标尚未完全确定。编码β-catenin的基因突变在肝细胞癌中过度表达。我们的研究目的是将肝细胞癌中β-catenin的分子表达与已知的预后标志物相关联：我们对确诊为肝细胞癌的成年患者进行了一项观察性和前瞻性队列研究，并在术中采集了非肿瘤和肿瘤肝实质样本，以研究肝细胞癌中β-catenin的分子表达与已知预后标志物的相关性：共收集了81份样本，其中48份符合纳入标准。最终样本分为肝硬化肝细胞癌诊断患者和非肝硬化肝细胞癌诊断患者，前者31例（64.6%），后者17例（35.4%）。我们发现，β-catenin的过表达和中性粒细胞/淋巴细胞比值与无病生存率独立相关，β-catenin的过表达和分子抑制也独立相关：结论：与非肿瘤组织相比，肝细胞癌中β-catenin的分子过表达与较差的无病生存期相关，而β-catenin的分子过表达与中性粒细胞/淋巴细胞比值过高的组合会使预后恶化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Surgery 医学-外科

CiteScore

5.40

自引率

5.30%

发文量

687

审稿时长

64 days

期刊介绍： For 66 years, Surgery has published practical, authoritative information about procedures, clinical advances, and major trends shaping general surgery. Each issue features original scientific contributions and clinical reports. Peer-reviewed articles cover topics in oncology, trauma, gastrointestinal, vascular, and transplantation surgery. The journal also publishes papers from the meetings of its sponsoring societies, the Society of University Surgeons, the Central Surgical Association, and the American Association of Endocrine Surgeons.